CN1238363C - 吡喃葡糖氧基吡唑衍生物及其在药物中的应用 - Google Patents

吡喃葡糖氧基吡唑衍生物及其在药物中的应用 Download PDF

Info

Publication number
CN1238363C
CN1238363C CNB018228836A CN01822883A CN1238363C CN 1238363 C CN1238363 C CN 1238363C CN B018228836 A CNB018228836 A CN B018228836A CN 01822883 A CN01822883 A CN 01822883A CN 1238363 C CN1238363 C CN 1238363C
Authority
CN
China
Prior art keywords
methyl
glucopyranosyloxy
isopropyl
acyl
methylpyrazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB018228836A
Other languages
English (en)
Chinese (zh)
Other versions
CN1492873A (zh
Inventor
藤仓秀纪
伏见信彦
西村俊洋
中林毅司
伊佐治正幸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18867638&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1238363(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Publication of CN1492873A publication Critical patent/CN1492873A/zh
Application granted granted Critical
Publication of CN1238363C publication Critical patent/CN1238363C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB018228836A 2000-12-28 2001-12-25 吡喃葡糖氧基吡唑衍生物及其在药物中的应用 Expired - Lifetime CN1238363C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP403534/2000 2000-12-28
JP403534/00 2000-12-28
JP2000403534 2000-12-28

Publications (2)

Publication Number Publication Date
CN1492873A CN1492873A (zh) 2004-04-28
CN1238363C true CN1238363C (zh) 2006-01-25

Family

ID=18867638

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018228836A Expired - Lifetime CN1238363C (zh) 2000-12-28 2001-12-25 吡喃葡糖氧基吡唑衍生物及其在药物中的应用

Country Status (30)

Country Link
US (5) US7084123B2 (enExample)
EP (1) EP1354888B1 (enExample)
JP (2) JP4035052B2 (enExample)
KR (1) KR100701437B1 (enExample)
CN (1) CN1238363C (enExample)
AR (1) AR032065A1 (enExample)
AT (1) ATE431830T1 (enExample)
AU (1) AU2002225356B2 (enExample)
BR (1) BRPI0116607B8 (enExample)
CA (1) CA2432145C (enExample)
CY (1) CY1109309T1 (enExample)
CZ (1) CZ305971B6 (enExample)
DE (1) DE60138768D1 (enExample)
DK (1) DK1354888T3 (enExample)
ES (1) ES2326158T3 (enExample)
HU (1) HU228915B1 (enExample)
IL (2) IL156678A0 (enExample)
MX (1) MXPA03005923A (enExample)
MY (1) MY136581A (enExample)
NO (1) NO326410B1 (enExample)
NZ (1) NZ526715A (enExample)
PE (1) PE20020722A1 (enExample)
PL (1) PL209375B1 (enExample)
PT (1) PT1354888E (enExample)
RU (1) RU2317302C2 (enExample)
SI (1) SI1354888T1 (enExample)
SK (1) SK287786B6 (enExample)
TW (1) TWI231298B (enExample)
WO (1) WO2002053573A1 (enExample)
ZA (1) ZA200304905B (enExample)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
EP1338603B1 (en) 2000-11-02 2010-01-20 Ajinomoto Co., Inc. Novel pyrazole derivatives and diabetes remedies containing the same
US7053060B2 (en) * 2000-11-30 2006-05-30 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
RU2317302C2 (ru) 2000-12-28 2008-02-20 Киссеи Фармасьютикал Ко., Лтд. Производные глюкопиранозилоксипиразола и их применение в лекарственных средствах
TW593329B (en) * 2001-02-26 2004-06-21 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives and pharmaceutical uses thereof
DE60237580D1 (de) 2001-02-27 2010-10-21 Kissei Pharmaceutical Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
ES2321815T3 (es) 2001-04-04 2009-06-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Combinacion terapeutica que comprende inhibidores de reabsorcion e glucosa y moduladores ppar.
ATE442148T1 (de) 2001-04-04 2009-09-15 Ortho Mcneil Janssen Pharm Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren
CA2672001A1 (en) 2001-04-27 2002-11-07 Ajinomoto Co., Inc. N-substituted pyrazole-o-glycoside derivatives and therapeutic agent for diabetes containing the same
CA2448741C (en) 2001-05-30 2010-06-22 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
EP1432720A1 (en) * 2001-09-05 2004-06-30 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
US7956041B2 (en) 2002-04-26 2011-06-07 Ajinomoto Co., Inc. Prophylactic and therapeutic agent of diabetes mellitus
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
JP2006501205A (ja) * 2002-07-30 2006-01-12 カリキオン インコーポレイテッド エゼチミブ組成物、並びにコレステロールに関連した良性および悪性の腫瘍を治療する方法
CN100351263C (zh) * 2002-08-08 2007-11-28 橘生药品工业株式会社 吡唑衍生物、含该衍生物的医药组合物、其医药用途及用于制备的中间体
CA2494179C (en) * 2002-08-08 2012-04-24 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
RU2322449C2 (ru) * 2002-08-09 2008-04-20 Тайсо Фармасьютикал Ко., Лтд. ПРОИЗВОДНЫЕ АРИЛ 5-ТИО-β-D-ГЛЮКОПИРАНОЗИДА И ТЕРАПЕВТИЧЕСКИЕ СРЕДСТВА ПРИ ДИАБЕТЕ, СОДЕРЖАЩИЕ ИХ
ZA200501549B (en) * 2002-08-23 2006-07-26 Kissei Pharmaceutical Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof and intermediate for the production thereof
JP2004137245A (ja) * 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
AU2003262262A1 (en) * 2002-08-27 2004-03-19 Kissei Pharmaceutical Co., Ltd. Pyrazole derivatives, medicinal composition containing the same, and medicinal use thereof
WO2004019926A1 (ja) * 2002-08-30 2004-03-11 Mitsubishi Pharma Corporation 心不全の予防及び／又は治療剤
AU2003272903A1 (en) * 2002-10-04 2004-04-23 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
EP1568380A4 (en) * 2002-12-04 2009-10-21 Kissei Pharmaceutical PREVENTION OR TREATMENT OF DISEASES DUE TO HYPERGLYCEMIA
JP4679155B2 (ja) * 2002-12-25 2011-04-27 キッセイ薬品工業株式会社 含窒素複素環誘導体、それを含有する医薬組成物およびその医薬用途
DK1628685T3 (da) 2003-04-25 2011-03-21 Gilead Sciences Inc Antivirale phosphonatanaloge
JP4708187B2 (ja) * 2003-06-20 2011-06-22 キッセイ薬品工業株式会社 ピラゾール誘導体、それを含有する医薬組成物及びその製造中間体
RS53365B (sr) 2003-08-01 2014-10-31 Mitsubishi Tanabe Pharma Corporation Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavisan od natrijuma
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
UA86042C2 (en) 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
CA2539032A1 (en) * 2003-08-26 2005-03-10 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pirazoles, drugs containing said compounds the use and production method thereof
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
GB2423927A (en) * 2003-08-29 2006-09-13 Cotherix Inc Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US20080045466A1 (en) * 2004-07-21 2008-02-21 Kenji Katsuno Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
AU2005330489B2 (en) 2004-07-27 2011-08-25 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti HIV agents
US20060063719A1 (en) * 2004-09-21 2006-03-23 Point Therapeutics, Inc. Methods for treating diabetes
WO2006034435A2 (en) * 2004-09-21 2006-03-30 Point Therapeutics, Inc. Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
TWI365186B (en) 2005-01-31 2012-06-01 Mitsubishi Tanabe Pharma Corp Indole derivatives
US8022192B2 (en) * 2005-03-17 2011-09-20 Kissei Pharmaceutical Co., Ltd. Process for production of glucopyranosyloxypyrazole derivative
RU2008106461A (ru) * 2005-07-22 2009-08-27 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Способы получения производных пиразол-о-гликозида и новых промежуточных соединений для применения в указанных способах
UY29694A1 (es) * 2005-07-28 2007-02-28 Boehringer Ingelheim Int Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido
MY145464A (en) * 2005-08-31 2012-02-15 Hoffmann La Roche Pyrazolone derivatives as 11-beta hsd1 inhibitors
UY30082A1 (es) 2006-01-11 2007-08-31 Boehringer Ingelheim Int Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos
CN100384416C (zh) * 2006-03-20 2008-04-30 杨军 一种用于治疗心血管疾病的药物组合物
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
TWI418556B (zh) 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
CN101611032B (zh) 2006-12-04 2012-07-18 詹森药业有限公司 作为抗糖尿病药的含噻吩基的吡喃葡糖基衍生物
BRPI0719941A2 (pt) 2006-12-06 2014-04-22 Smithkline Beecham Corp Composto, uso de um composto, método para o tratamento de distúrbios ou condições metabólicos, composição farmacêutica, e, processo para a preparação de uma composição farmacêutica
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
NO2200606T3 (enExample) 2007-09-10 2018-03-24
JP5144683B2 (ja) * 2007-12-27 2013-02-13 キッセイ薬品工業株式会社 ピラゾール誘導体のモノセバシン酸塩
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
PE20110219A1 (es) 2008-07-08 2011-03-31 Gilead Sciences Inc Sales del compuesto n-[(s)({[(2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il]oxi}metil)fenoxifosfinoil]-l-alaninato de etilo como inhibidores de vih
WO2010023594A1 (en) * 2008-08-28 2010-03-04 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
US20100113581A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
US20100113583A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
WO2010045417A2 (en) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
WO2010045522A2 (en) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
WO2010045563A2 (en) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20100167989A1 (en) * 2008-10-23 2010-07-01 Auspex Pharmaceuticals, Inc. Isopropoxyphenylmethyl inhibitors of sglt2
SG173619A1 (en) 2009-02-13 2011-09-29 Boehringer Ingelheim Int Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
US20120071401A1 (en) * 2009-04-10 2012-03-22 Amylin Pharamaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
US20120053330A1 (en) * 2009-04-30 2012-03-01 Daniel Edward Patterson Chemical Process
US20100331419A1 (en) * 2009-06-25 2010-12-30 Aronne Louis J Combination Therapies for the Treatment of Obesity
US20100331420A1 (en) * 2009-06-26 2010-12-30 Aronne Louis J Combination Therapies for the Treatment of Obesity
WO2011008490A2 (en) * 2009-06-29 2011-01-20 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
JP5658751B2 (ja) 2009-07-10 2015-01-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ １−（β−Ｄ−グルコピラノシル）−４−メチル−３−［５−（４−フルオロフェニル）−２−チエニルメチル］ベンゼンのための結晶化方法
US20110015663A1 (en) * 2009-07-17 2011-01-20 Aronne Louis J Combination Therapies for the Treatment of Obesity
US20110082407A1 (en) * 2009-10-01 2011-04-07 Aronne Louis J Combination Therapies for the Treatment of Obesity
PL2488515T3 (pl) * 2009-10-14 2017-07-31 Janssen Pharmaceutica Nv Sposób wytwarzania związków użytecznych jako inhibitory sglt2
EA021983B1 (ru) 2009-11-02 2015-10-30 Пфайзер Инк. Производные диоксабицикло[3.2.1]октан-2,3,4-триола
US9199914B2 (en) * 2010-02-03 2015-12-01 Meh Associates, Inc. Multiple substituted fluoromethanes as selective and bioactive isosteres
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2013523681A (ja) 2010-03-30 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用
LT2568988T (lt) 2010-05-11 2016-09-12 Janssen Pharmaceutica, N.V. Farmacinės kompozicijos, apimančios 1-(beta-d-gliukopiranozil)-2-tienilmetilbenzeno darinius kaip sglt inhibitorius
RU2596787C2 (ru) 2010-07-09 2016-09-10 БиЭйчВи ФАРМА, ИНК. Комбинированная система доставки с немедленным/замедленным высвобождением для лекарственных средств с коротким периодом полувыведения, в том числе для ремоглифлозина
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2013109241A1 (en) * 2011-01-10 2013-07-25 Muhammed Majeed Anti-obesity potential of calebin a
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
KR101913587B1 (ko) 2011-04-13 2018-10-31 얀센 파마슈티카 엔.브이. Sglt2의 억제제로서 유용한 화합물의 제조 방법
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
KR20140030231A (ko) 2011-06-03 2014-03-11 베링거 인겔하임 인터내셔날 게엠베하 신경이완제로 치료받는 환자에서 대사 장애를 치료하기 위한 ｓｇｌｔ－２ 억제제
RU2500407C2 (ru) * 2012-02-20 2013-12-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Средство, обладающее мочегонным действием
RU2517091C2 (ru) * 2012-02-20 2014-05-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации) Средство, обладающее мочегонным действием
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
FI2981269T3 (fi) 2013-04-04 2023-09-27 Boehringer Ingelheim Vetmedica Gmbh Aineenvaihduntahäiriöiden hoito hevoseläimillä
RS64990B1 (sr) 2013-12-17 2024-01-31 Boehringer Ingelheim Vetmedica Gmbh Sglt-2 inhibitor za primenu u lečenju metaboličkog poremećaja kod životinja iz roda mačaka
US10471502B2 (en) 2013-12-26 2019-11-12 Posco Continuous casting and rolling apparatus and method
EA201891406A1 (ru) 2014-01-23 2018-12-28 Бёрингер Ингельхайм Ветмедика Гмбх Лечение метаболических расстройств у представителей собачьих
NZ723781A (en) 2014-04-01 2022-09-30 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
US10555958B2 (en) 2014-09-25 2020-02-11 Boehringer Ingelheim Vetmedica Gmbh Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
KR200484486Y1 (ko) * 2016-05-09 2017-09-12 연세대학교 원주산학협력단 시료채취장치
AU2017344882A1 (en) 2016-10-19 2019-03-28 Boehringer Ingelheim International Gmbh Combinations comprising an SSAO/VAP-1 inhibitor and a SGLT2 inhibitor, uses thereof
ES2969496T3 (es) 2017-08-01 2024-05-20 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2- il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
PL3716979T3 (pl) 2017-11-30 2025-08-04 Idorsia Pharmaceuticals Ltd Połączenie pochodnej 4-pirymidynosulfamidu z inhibitorem sglt-2 do leczenia chorób związanych w endoteliną
WO2019193572A1 (en) * 2018-04-05 2019-10-10 Glenmark Pharmaceuticals Limited An improved process for the preparation remogliflozin etabonate or pharmaceutically acceptable salt, solvate, hydrate thereof
AU2019254371A1 (en) 2018-04-17 2020-10-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
JP7425793B2 (ja) 2018-10-29 2024-01-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用
CN112955215B (zh) 2018-10-29 2024-05-17 勃林格殷格翰国际有限公司 吡啶基磺酰胺衍生物、药物组合物及其用途
BR112022010385A2 (pt) 2019-11-28 2022-08-23 Boehringer Ingelheim Vetmedica Gmbh Uso de inibidores de sglt-2 na secagem de mamíferos não humanos
CN118615450A (zh) 2020-02-17 2024-09-10 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂用于预防和/或治疗猫科动物的心脏疾病的用途
EP4376819A1 (en) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
CN117715640A (zh) 2021-07-28 2024-03-15 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂用于在不包括猫科动物的非人哺乳动物，特别是犬科动物中预防和/或治疗心脏疾病的用途
US20240307426A1 (en) 2021-07-28 2024-09-19 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
EP4456872A1 (en) 2021-12-30 2024-11-06 NewAmsterdam Pharma B.V. Obicetrapib and sglt2 inhibitor combination
TW202412756A (zh) 2022-05-25 2024-04-01 德商百靈佳殷格翰維美迪加股份有限公司 包含sglt-2抑制劑之水性醫藥組合物
WO2024184293A1 (en) 2023-03-06 2024-09-12 Boehringer Ingelheim Vetmedica Gmbh Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
AR132497A1 (es) 2023-04-24 2025-07-02 Newamsterdam Pharma B V Combinación de obicetrapib amorfo e inhibidor de sglt2
AU2024277852A1 (en) 2023-05-24 2025-10-16 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan
WO2024240632A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
WO2024254352A1 (en) * 2023-06-06 2024-12-12 Vogenx Sglt1 inhibitor and incretin combinations for treating metabolic disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2659655B1 (fr) 1990-03-19 1992-07-24 Union Pharma Scient Appl Nouveaux derives d'oxypyrazole antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant.
US5264451A (en) * 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
KR100591585B1 (ko) * 1999-08-31 2006-06-20 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실옥시피라졸 유도체, 그것을 함유하는 의약조성물 및 그 제조 중간체
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
EP1338603B1 (en) 2000-11-02 2010-01-20 Ajinomoto Co., Inc. Novel pyrazole derivatives and diabetes remedies containing the same
RU2317302C2 (ru) 2000-12-28 2008-02-20 Киссеи Фармасьютикал Ко., Лтд. Производные глюкопиранозилоксипиразола и их применение в лекарственных средствах
TW593329B (en) * 2001-02-26 2004-06-21 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives and pharmaceutical uses thereof
JP2003072176A (ja) * 2001-09-03 2003-03-12 Olympus Optical Co Ltd 画像記録装置
EP1432720A1 (en) 2001-09-05 2004-06-30 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
US6731109B2 (en) * 2002-07-12 2004-05-04 Wabash Technologies, Inc. Magnetic position sensor having a stepped magnet interface

Also Published As

Publication number Publication date
JPWO2002053573A1 (ja) 2004-05-13
CZ305971B6 (cs) 2016-06-01
SK8092003A3 (en) 2004-01-08
MXPA03005923A (es) 2004-01-26
BRPI0116607B1 (pt) 2016-12-27
MY136581A (en) 2008-10-31
WO2002053573A1 (en) 2002-07-11
US20040063646A1 (en) 2004-04-01
BRPI0116607B8 (pt) 2021-05-25
US7465713B2 (en) 2008-12-16
KR100701437B1 (ko) 2007-03-30
US20060025352A1 (en) 2006-02-02
AR032065A1 (es) 2003-10-22
SK287786B6 (sk) 2011-09-05
CA2432145C (en) 2010-07-13
US7393838B2 (en) 2008-07-01
DK1354888T3 (da) 2009-09-21
NO20032909D0 (no) 2003-06-24
CY1109309T1 (el) 2014-07-02
PE20020722A1 (es) 2002-09-30
HK1062914A1 (en) 2004-12-03
US20090093419A1 (en) 2009-04-09
US7429568B2 (en) 2008-09-30
JP2008007519A (ja) 2008-01-17
SI1354888T1 (sl) 2009-10-31
AU2002225356B2 (en) 2008-03-06
EP1354888B1 (en) 2009-05-20
CN1492873A (zh) 2004-04-28
ES2326158T3 (es) 2009-10-02
HU228915B1 (en) 2013-06-28
PL209375B1 (pl) 2011-08-31
RU2317302C2 (ru) 2008-02-20
CA2432145A1 (en) 2002-07-11
KR20030063482A (ko) 2003-07-28
JP4035052B2 (ja) 2008-01-16
HUP0302550A2 (hu) 2003-11-28
CZ20031753A3 (cs) 2003-10-15
PT1354888E (pt) 2009-07-27
TWI231298B (en) 2005-04-21
IL156678A0 (en) 2004-01-04
EP1354888A4 (en) 2004-01-28
NO326410B1 (no) 2008-12-01
DE60138768D1 (de) 2009-07-02
JP4758964B2 (ja) 2011-08-31
PL365284A1 (en) 2004-12-27
US20060035847A1 (en) 2006-02-16
EP1354888A1 (en) 2003-10-22
HUP0302550A3 (en) 2009-08-28
ZA200304905B (en) 2004-06-24
US20060094667A1 (en) 2006-05-04
NZ526715A (en) 2005-02-25
US7989424B2 (en) 2011-08-02
BR0116607A (pt) 2004-04-20
ATE431830T1 (de) 2009-06-15
NO20032909L (no) 2003-08-27
US7084123B2 (en) 2006-08-01
IL156678A (en) 2010-03-28

Similar Documents

Publication Publication Date Title
CN1238363C (zh) 吡喃葡糖氧基吡唑衍生物及其在药物中的应用
JP4540475B2 (ja) ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
CN1784415A (zh) 稠合杂环衍生物、含该衍生物的医药组合物及其医药用途
US7635684B2 (en) Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
CN1950389A (zh) 含氮稠环衍生物，含该衍生物的药物组合物，和其作为药物的用途
CN1537114A (zh) 含氮的杂环衍生物、含有该衍生物的药物组合物、其药物应用以及用于该衍生物制备的中间体
JP4708187B2 (ja) ピラゾール誘導体、それを含有する医薬組成物及びその製造中間体
CN1934103A (zh) 稠杂环衍生物，包含稠杂环衍生物的药物组合物及其医药用途
JP5066512B2 (ja) ピラゾール誘導体の製造方法およびその製造用中間体
CN1934122A (zh) 稠合杂环衍生物、包含该稠合杂环衍生物的药物组合物、及其药学应用
CN100351263C (zh) 吡唑衍生物、含该衍生物的医药组合物、其医药用途及用于制备的中间体
CN100413878C (zh) 吡唑衍生物、含该衍生物的医药组合物、其医药用途及用于制备的中间体
HK1062914B (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines
HK1082743B (en) Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1062914

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20060125